Trial DesignHigh-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial☆☆
Section snippets
Trial design and methods
INVESTED is a randomized, double-blind, parallel-group, active-controlled, 2-arm study comparing the effectiveness of high-dose versus standard-dose influenza vaccine in reducing all-cause mortality or cardiopulmonary hospitalizations in high-risk cardiovascular patients. The trial was designed by members of the Executive and Steering Committees in collaboration with the National Heart, Lung, and Blood Institute (NHLBI). The trial has been registered on ClinicalTrials.gov (NCT02787044).
Discussion
Influenza infection is associated with substantial morbidity and mortality in patients with cardiovascular disease. Although influenza vaccination is recommended in patients with cardiovascular conditions, the effectiveness may be limited because of relative immunosenescence in patients with cardiovascular conditions, and data from several trials and a meta-analysis suggest that a more effective vaccination strategy could potentially mitigate the reduced immune response. INVESTED will directly
Funding
INVESTED is funded by the NHLBI (U01 HL130163 and U01 HL130204). Additional funds for site payments and vaccine are provided by Sanofi Pasteur, which has no scientific role in the INVESTED trial. Additional funds for the biological specimen acquisition are provided by grants from Heart and Stroke Foundation of Canada (ERLI024) and the Mount Sinai Hospital/University Health Network AMO Innovation Fund (21502002).
Disclaimer
The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the NHLBI; the National Institutes of Health; the US Departments of Veterans Affairs, and Health and Human Services; or the US Government.
References (40)
- et al.
Role of acute infection in triggering acute coronary syndromes
Lancet Infect Dis
(2010) - et al.
Decreased immune responses to influenza vaccination in patients with heart failure
J Card Fail
(2009) - et al.
Prevention of serious events in adults 65 years of age or older: a comparison between high-dose and standard-dose inactivated influenza vaccines
Vaccine
(2015) - et al.
Influenza vaccination in patients with chronic heart failure: the PARADIGM-HF trial
JACC Heart Fail
(2016) - et al.
Myocardial dysfunction during H1N1 influenza infection
J Crit Care
(2013) - et al.
Design and rationale for the Influenza vaccination After Myocardial Infarction (IAMI) trial. A registry-based randomized clinical trial
Am Heart J
(2017) - et al.
Influenza and the winter increase in mortality in the United States, 1959-1999
Am J Epidemiol
(2004) - et al.
Risk of myocardial infarction and stroke after acute infection or vaccination
N Engl J Med
(2004) - et al.
Acute myocardial infarction after laboratory-confirmed influenza infection
N Engl J Med
(2018) - et al.
ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Circulation
(2013)
Influenza vaccination as secondary prevention for cardiovascular disease: a science advisory from the American Heart Association/American College of Cardiology
Circulation
2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)
Eur Heart J
Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly
N Engl J Med
Effects of annual influenza vaccination on winter mortality in elderly people with chronic heart disease
Eur Heart J
Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis
JAMA
Double dose vs. standard dose influenza vaccination in patients with heart failure: a pilot study
Eur J Heart Fail
Efficacy of high-dose versus standard-dose influenza vaccine in older adults
N Engl J Med
Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2017-18 influenza season
MMWR Recomm Rep
Evaluation of survival data and two new rank order statistics arising in its consideration
Cancer Chemother Rep
Nonparametric estimation from incomplete observations
Cited by (0)
Declarations of interest: O. V. has received research funding from Novartis and Sanofi-Pasteur. J. A. U. has received research funding from AstraZeneca, Novartis, and Sanofi Aventis; consultancy fees from Amgen, Boehringer Ingelheim (BI), Janssen, Merck, Novartis, and Sanofi-Pasteur; and honoraria for lectures from BI and Janssen. S. D. S. has received research funding from Sanofi-Pasteur. H. K. T. has received research funding from Sanofi Pasteur, MedImmune, and Gilead and serves as a safety consultant for VaxInnate and Seqiris. A. J. M. has received research support from GlaxoSmithKline and Sanofi Pasteur. A. F. H. has received consultancy fees from Amgen, AstraZeneca, Bayer, BI, Boston Scientific, Merck, Novartis, and Sanofi Aventis and research support from AstraZeneca, GlaxoSmithKline, Luitpold, Merck, and Novartis. Dr D. L. B. discloses the following: Advisory Board: Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care; Chair: American Heart Association Quality Oversight Committee; Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute), Cleveland Clinic, Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine, Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Vice-Chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; clinical trial steering committee), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Population Health Research Institute (clinical trial steering committee), Slack Publications (Chief Medical Editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Research Funding: Abbott, Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb (BMS), Chiesi, Eisai, Ethicon, Forest Laboratories, Idorsia, Ironwood, Ischemix, Lilly, Medtronic, PhaseBio, Pfizer, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease); Site Co-Investigator: Biotronik, Boston Scientific, St Jude Medical (now Abbott), Svelte; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Merck, PLx Pharma, Takeda. C. P. C. receives research grants from Amgen, Arisaph, BI, BMS, Daiichi Sankyo, Janssen, Merck, and Takeda; consulting fees from Alnylam, Amarin, Amgen, Arisaph, Astra Zeneca, BI, BMS, Eisai, GlaxoSmithKline, Kowa, Lipimedix, Merck, Pfizer, Regeneron, Sanofi, and Takeda. S. G. G. receives research grant support and speaker/consulting honoraria from Amgen, AstraZeneca, Bayer, BI, Bristol Myers Squibb, CSL Behring, Daiichi-Sankyo, Eli Lilly, Fenix Group International, Ferring Pharmaceuticals, GlaxoSmithKline, Janssen/Johnson & Johnson, Luitpold Pharmaceuticals, Matrizyme, Merck, Novartis, Pfizer, Regeneron, Sanofi, Servier, Tenax Therapeutics, Heart and Stroke Foundation of Ontario/University of Toronto, Canadian Heart Research Centre and MD Primer, Canadian VIGOUR Centre, and Duke Clinical Research Institute. I. A. receives consultant fees from Amgen, Arca, AstraZeneca, BI, Cyberonics, Novartis, and Zensun. D. L. D. serves as a consultant to the National Institutes of Health and the Food and Drug Administration, and serves as an independent biostatistician serving as a member of a trial steering committee or data and safety monitoring boards for Actelion, Amgen, Astra-Zeneca, Bayer, BI, GlaxoSmithKline, Merck, Novartis, Otsuka, Pfizer, Roche, Sanofi-Aventis, Duke Clinical Research Institute, Harvard Clinical Research Institute, and McMaster University Population Health Research Institute. J. T. served as a consultant for Sanofi Pastuer and received in-kind research support from Quidel Corporation. J. W. has served on the data and safety monitoring board for Sanofi-Pasteur, and the company for which J. W. works and is part-owner has contracts with many companies that produce drugs, biologics, and devices, including Sanofi Pasteur for development of influenza vaccines. K. N. and C. W. Y. report no disclosures.
- ☆☆
RCT# NCT02787044.
- 1
The first 2 authors contributed equally to the manuscript.